Trials / Terminated
TerminatedNCT01412528
Phase II Study to Standardize Allergen Extracts: Determination of Biological Activity in HEP Units
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Today a variety of diagnostic tools to detect allergenic agents are available such as skin tests, provocation tests and blood tests. Due to its high sensitivity and low costs the skin prick test is the most commonly used test to identify allergies in patients. By using this kind of skin test, up to 25 different agents can be tested in parallel, rendering the skin prick test a cheap, easy-to-handle and rapid diagnostic tool. However, as research proceeds, new tools appear with the intention to make future applications even more convenient -for both, the patient and the physician. For that purpose the development of the so called "Easyprick" Allergen Test System is under way, consisting of a foil that carries ready-to-use, allergen-soaked sponges which can easily be applied to the skin after pricking. Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. In order to control variability and to achieve consistency and reproducibility for optimal safety and sensitivity/specificity, it is essential to standardize the amount of allergen used in prick tests. The present study aims to standardize eight allergen extracts by using this method. Standardized extracts will then be applied in the Easyprick Allergen Test System which will be evaluated and compared to the conventional prick test in a second study. * Trial with medicinal product
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Allergen extracts |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2011-08-09
- Last updated
- 2011-08-09
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01412528. Inclusion in this directory is not an endorsement.